Catalog No.
PHE08401
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human NF2 (Asp30-Leu239).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Merlin, Neurofibromin-2, Schwannomerlin, NF2, SCH, Moesin-ezrin-radixin-like protein, Schwannomin
Purification
Purified by antigen affinity column.
Accession
P35240
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Clinical benefits of immune checkpoint inhibitors for malignant peripheral nerve sheath tumors with NF2 mutation: a case report., PMID:40469286
Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas., PMID:40447281
Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma., PMID:40362535
Multiplatform molecular analyses reveal two molecular subgroups of NF2-related schwannomatosis vestibular schwannomas with distinct tumour microenvironment and therapeutic vulnerabilities., PMID:40343504
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model., PMID:39763968
Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation., PMID:39685944
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas., PMID:39212325
PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas., PMID:38828669
Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis., PMID:38776485
Development of a vestibular schwannoma tumor slice model for pharmacological testing., PMID:38387803
MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF., PMID:37917191
Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing., PMID:37887551
New classification and approaches to the treatment of schwannomatosis., PMID:37830475
Current progress in genomics and targeted therapies for neurofibromatosis type 2., PMID:37468280
The genetic landscape and possible therapeutics of neurofibromatosis type 2., PMID:37217995
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma., PMID:37010875
Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series., PMID:36975476
Treatment of neurofibromatosis type II with anlotinib: a case report and literature review., PMID:36689644
A Comprehensive Overview of Pediatric Neoplasms at the Craniocervical Junction: Meningiomas, Schwannomas, and Chordomas., PMID:36479403
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain., PMID:36038003
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma., PMID:35715365
Primary central nervous system histiocytic sarcoma with somatic NF2 mutation: Case report and review of literature., PMID:35652545
Multiple craniospinal tumors in a pediatric patient with neurofibromatosis type 2: a case report., PMID:35469077
Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the NF2:c.784C>T p.(Arg262*) variant., PMID:35445657
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates., PMID:35298296
LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma., PMID:35287088
[Current Topics on Precision Medicine for Neurofibromatosis Type 2]., PMID:35169095
Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment., PMID:34917175
Multiplex Detection of Magnetic Beads Using Offset Field Dependent Frequency Mixing Magnetic Detection., PMID:34502749
Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis., PMID:34214711
Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case., PMID:33775351
Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma., PMID:33572546
mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition., PMID:33273014
Current Management of Large Vestibular Schwannomas for NF2 Patients in a National Reference Center., PMID:33270257
Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors., PMID:32767156
Long-term therapy with Bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature., PMID:32697470
Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality., PMID:32548671
Rapid development of an atypical meningioma during Nivolumab therapy for metastatic renal cell carcinoma., PMID:32502948
Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence., PMID:32124552
Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors., PMID:32088190
Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis., PMID:31936793
Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients., PMID:31902875
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2., PMID:31848332
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma., PMID:31626572
A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma., PMID:31301014
Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes., PMID:31254266
Long-term therapy with bevacizumab in a young patient affected by NF-2: a case report and review of the literature., PMID:30640792
Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities., PMID:30373466
For research use only. Not for human or drug use.
